Display options
Cite
Tian H, Yang W, Hu Y, et al. Estimating cancer incidence based on claims data from medical insurance systems in two areas lacking cancer registries in China. EClinicalMedicine. 2020;20:100312doi: 10.1016/j.eclinm.2020.100312.
Tian, H., Yang, W., Hu, Y., Liu, Z., Chen, L., Lei, L., Zhang, F., Cai, F., Xu, H., Liu, M., Guo, C., Chen, Y., Xiao, P., Chen, J., Ji, P., Fang, Z., Liu, F., Liu, Y., Pan, Y., Dos-Santos-Silva, I., He, Z., & Ke, Y. (2020). Estimating cancer incidence based on claims data from medical insurance systems in two areas lacking cancer registries in China. EClinicalMedicine, 20100312. https://doi.org/10.1016/j.eclinm.2020.100312
Tian, Hongrui, et al. "Estimating cancer incidence based on claims data from medical insurance systems in two areas lacking cancer registries in China." EClinicalMedicine vol. 20 (2020): 100312. doi: https://doi.org/10.1016/j.eclinm.2020.100312
Tian H, Yang W, Hu Y, Liu Z, Chen L, Lei L, Zhang F, Cai F, Xu H, Liu M, Guo C, Chen Y, Xiao P, Chen J, Ji P, Fang Z, Liu F, Liu Y, Pan Y, Dos-Santos-Silva I, He Z, Ke Y. Estimating cancer incidence based on claims data from medical insurance systems in two areas lacking cancer registries in China. EClinicalMedicine. 2020 Mar 20;20:100312. doi: 10.1016/j.eclinm.2020.100312. eCollection 2020 Mar. PMID: 32215367; PMCID: PMC7090368.
Copy Download .nbib Format: NLM
Share it on

EClinicalMedicine. 2020 Mar 20;20:100312. doi: 10.1016/j.eclinm.2020.100312. eCollection 2020 Mar.

Estimating cancer incidence based on claims data from medical insurance systems in two areas lacking cancer registries in China.

EClinicalMedicine

Hongrui Tian, Wei Yang, Yanjun Hu, Zhen Liu, Lei Chen, Liang Lei, Fan Zhang, Fen Cai, Huawen Xu, Mengfei Liu, Chuanhai Guo, Yun Chen, Ping Xiao, Junhui Chen, Ping Ji, Zhengyu Fang, Fangfang Liu, Ying Liu, Yaqi Pan, Isabel Dos-Santos-Silva, Zhonghu He, Yang Ke

Affiliations

  1. Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing, China.
  2. Cancer Hospital of Shantou University Medical College, Guangdong Province, China.
  3. Healthcare Security Administration of Hua County, Henan Province, China.
  4. Peking University Shenzhen Hospital, Guangdong Province, China.
  5. Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.

PMID: 32215367 PMCID: PMC7090368 DOI: 10.1016/j.eclinm.2020.100312

Abstract

BACKGROUND: We aimed to establish a Medical-Insurance-System-based Cancer Surveillance System (MIS-CASS) in China and evaluate the completeness and timeliness of this system through reporting cancer incidence rates using claims data in two regions in northern and southern China.

METHODS: We extracted claims data from medical insurance systems in Hua County of Henan Province, and Shantou City in Guangdong Province in China from Jan 1, 2012 to Jun 30, 2019. These two regions have been considered to be high risk regions for oesophageal cancer. We developed a rigorous procedure to establish the MIS-CASS, which includes data extraction, cleaning, processing, case ascertainment, privacy protection, etc. Text-based diagnosis in conjunction with ICD-10 codes were used to determine cancer diagnosis.

FINDINGS: In 2018, the overall age-standardised (Segi population) incidence rates (ASR World) of cancer in Hua County and Shantou City were 167·39/100,000 and 159·78/100,000 respectively. In both of these areas, lung cancer and breast cancer were the most common cancers in males and females respectively. Hua County is a high-risk region for oesophageal cancer (ASR World: 25·95/100,000), whereas Shantou City is not a high-risk region for oesophageal cancer (ASR World: 11·43/100,000). However, Nanao island had the highest incidence of oesophageal cancer among all districts and counties in Shantou (ASR World: 36·39/100,000). The age-standardised male-to-female ratio for oesophageal cancer was lower in Hua County than in Shantou (1·69 vs. 4·02). A six-month lag time was needed to report these cancer incidences for the MIS-CASS.

INTERPRETATION: MIS-CASS efficiently reflects cancer burden in real-time, and has the potential to provide insight for improvement of cancer surveillance in China.

FUNDING: The National Key R&D Program of China (2016YFC0901404), the Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals (XXZ0204), the Sanming Project of Shenzhen (SZSM201612061), and the Shantou Science and Technology Bureau (190829105556145, 180918114960704).

© 2020 Published by Elsevier Ltd.

Keywords: Cancer incidence; Cancer surveillance; China; Claims data; Medical insurance system

Conflict of interest statement

The authors have no conflict of interest for the publication of this study.

References

  1. J Clin Epidemiol. 2019 Oct;114:141-149 - PubMed
  2. Int J Cancer. 2002 Nov 20;102(3):271-4 - PubMed
  3. BMC Med Res Methodol. 2018 May 8;18(1):38 - PubMed
  4. Gut. 2019 Feb;68(2):198-206 - PubMed
  5. Chin J Cancer Res. 2018 Feb;30(1):1-12 - PubMed
  6. Chin J Cancer Res. 2019 Aug;31(4):699-706 - PubMed
  7. Cancer Lett. 2017 Aug 10;401:63-71 - PubMed
  8. Health Serv Res. 2004 Dec;39(6 Pt 1):1733-49 - PubMed
  9. Eur J Epidemiol. 2007;22(1):43-8 - PubMed
  10. Int J Cancer. 2005 Jan 20;113(3):456-63 - PubMed
  11. Med Care. 2012 Aug;50(8):700-4 - PubMed
  12. Am J Gastroenterol. 2004 Jun;99(6):1141-4 - PubMed
  13. Cancer Detect Prev. 2002;26(3):197-202 - PubMed
  14. Asian Pac J Cancer Prev. 2012;13(12):6163-8 - PubMed
  15. Gastroenterology. 2017 Jul;153(1):166-177 - PubMed
  16. Eur J Cancer. 2009 Mar;45(5):756-64 - PubMed
  17. Eur J Cancer. 2009 Mar;45(5):747-55 - PubMed
  18. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed

Publication Types